Tenofovir	B:C3713958
alafenamide	I:C3713958
versus	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
for	O
the	O
treatment	O
of	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
chronic	O
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
infection	I:C0524909
:	O
a	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
phase	O
3	I:C0282461
,	O
non-inferiority	O
trial	I:C0008976
.	O

Tenofovir	O
alafenamide	I:C3713958
versus	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
for	O
the	O
treatment	O
of	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
chronic	O
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
infection	I:C0524909
:	O
a	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
phase	O
3	I:C0282461
,	O
non-inferiority	O
trial	I:C0008976
.	O

Tenofovir	O
alafenamide	I:C3713958
versus	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
for	O
the	O
treatment	O
of	O
HBeAg	B:C0392390
-	I:C0392390
positive	I:C0392390
chronic	O
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
infection	I:C0524909
:	O
a	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
phase	O
3	I:C0282461
,	O
non-inferiority	O
trial	I:C0008976
.	O

Tenofovir	O
alafenamide	I:C3713958
versus	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
for	O
the	O
treatment	O
of	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
chronic	B:C0524909
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
infection	I:C0524909
:	O
a	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
phase	O
3	I:C0282461
,	O
non-inferiority	O
trial	I:C0008976
.	O

Tenofovir	O
alafenamide	I:C3713958
versus	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
for	O
the	O
treatment	O
of	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
chronic	O
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
infection	I:C0524909
:	O
a	O
randomised	B:C0206034
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
phase	O
3	I:C0282461
,	O
non-inferiority	O
trial	I:C0008976
.	O

Tenofovir	O
alafenamide	I:C3713958
versus	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
for	O
the	O
treatment	O
of	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
chronic	O
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
infection	I:C0524909
:	O
a	O
randomised	O
,	O
double	B:C0013072
-	I:C0013072
blind	I:C0013072
,	O
phase	O
3	I:C0282461
,	O
non-inferiority	O
trial	I:C0008976
.	O

Tenofovir	O
alafenamide	I:C3713958
versus	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
for	O
the	O
treatment	O
of	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
chronic	O
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
infection	I:C0524909
:	O
a	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
phase	B:C0282461
3	I:C0282461
,	O
non-inferiority	O
trial	I:C0008976
.	O

Tenofovir	O
alafenamide	I:C3713958
versus	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
for	O
the	O
treatment	O
of	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
chronic	O
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
infection	I:C0524909
:	O
a	O
randomised	O
,	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
phase	O
3	I:C0282461
,	O
non-inferiority	B:C0008976
trial	I:C0008976
.	O

Tenofovir	B:C3713958
alafenamide	I:C3713958
is	O
a	O
novel	O
prodrug	O
formulated	O
to	O
deliver	O
the	O
active	O
metabolite	O
to	O
target	O
cells	O
more	O
efficiently	O
than	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
at	O
a	O
lower	O
dose	O
,	O
thereby	O
reducing	O
systemic	O
exposure	O
.	O

Tenofovir	O
alafenamide	I:C3713958
is	O
a	O
novel	O
prodrug	B:C0033262
formulated	O
to	O
deliver	O
the	O
active	O
metabolite	O
to	O
target	O
cells	O
more	O
efficiently	O
than	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
at	O
a	O
lower	O
dose	O
,	O
thereby	O
reducing	O
systemic	O
exposure	O
.	O

Tenofovir	O
alafenamide	I:C3713958
is	O
a	O
novel	O
prodrug	O
formulated	B:C0524527
to	O
deliver	O
the	O
active	O
metabolite	O
to	O
target	O
cells	O
more	O
efficiently	O
than	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
at	O
a	O
lower	O
dose	O
,	O
thereby	O
reducing	O
systemic	O
exposure	O
.	O

Tenofovir	O
alafenamide	I:C3713958
is	O
a	O
novel	O
prodrug	O
formulated	O
to	O
deliver	O
the	O
active	O
metabolite	B:C0870883
to	O
target	O
cells	O
more	O
efficiently	O
than	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
at	O
a	O
lower	O
dose	O
,	O
thereby	O
reducing	O
systemic	O
exposure	O
.	O

Tenofovir	O
alafenamide	I:C3713958
is	O
a	O
novel	O
prodrug	O
formulated	O
to	O
deliver	O
the	O
active	O
metabolite	O
to	O
target	O
cells	B:C0007634
more	O
efficiently	O
than	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
at	O
a	O
lower	O
dose	O
,	O
thereby	O
reducing	O
systemic	O
exposure	O
.	O

Tenofovir	O
alafenamide	I:C3713958
is	O
a	O
novel	O
prodrug	O
formulated	O
to	O
deliver	O
the	O
active	O
metabolite	O
to	O
target	O
cells	O
more	O
efficiently	O
than	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
at	O
a	O
lower	O
dose	O
,	O
thereby	O
reducing	O
systemic	O
exposure	O
.	O

In	O
patients	O
with	O
HIV	B:C0019693
,	O
tenofovir	O
alafenamide	I:C3713958
was	O
as	O
efficacious	O
as	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
,	O
with	O
reduced	O
bone	O
and	O
renal	O
toxic	I:C0595916
effects	O
.	O

In	O
patients	O
with	O
HIV	O
,	O
tenofovir	B:C3713958
alafenamide	I:C3713958
was	O
as	O
efficacious	O
as	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
,	O
with	O
reduced	O
bone	O
and	O
renal	O
toxic	I:C0595916
effects	O
.	O

In	O
patients	O
with	O
HIV	O
,	O
tenofovir	O
alafenamide	I:C3713958
was	O
as	O
efficacious	O
as	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
,	O
with	O
reduced	O
bone	O
and	O
renal	O
toxic	I:C0595916
effects	O
.	O

In	O
patients	O
with	O
HIV	O
,	O
tenofovir	O
alafenamide	I:C3713958
was	O
as	O
efficacious	O
as	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
,	O
with	O
reduced	O
bone	B:C0948168
and	O
renal	O
toxic	I:C0595916
effects	O
.	O

In	O
patients	O
with	O
HIV	O
,	O
tenofovir	O
alafenamide	I:C3713958
was	O
as	O
efficacious	O
as	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
,	O
with	O
reduced	O
bone	O
and	O
renal	B:C0595916
toxic	I:C0595916
effects	O
.	O

We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
two	O
drugs	B:C0013227
in	O
patients	O
with	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
chronic	O
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
(	I:C0524909
HBV	I:C0524909
)	I:C0524909
infection	I:C0524909
in	O
a	O
non-inferiority	O
study	I:C0008976
.	O

We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
two	O
drugs	O
in	O
patients	O
with	O
HBeAg	B:C0392390
-	I:C0392390
positive	I:C0392390
chronic	O
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
(	I:C0524909
HBV	I:C0524909
)	I:C0524909
infection	I:C0524909
in	O
a	O
non-inferiority	O
study	I:C0008976
.	O

We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
two	O
drugs	O
in	O
patients	O
with	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
chronic	B:C0524909
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
(	I:C0524909
HBV	I:C0524909
)	I:C0524909
infection	I:C0524909
in	O
a	O
non-inferiority	O
study	I:C0008976
.	O

We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
two	O
drugs	O
in	O
patients	O
with	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
chronic	O
hepatitis	I:C0524909
B	I:C0524909
virus	I:C0524909
(	I:C0524909
HBV	I:C0524909
)	I:C0524909
infection	I:C0524909
in	O
a	O
non-inferiority	B:C0008976
study	I:C0008976
.	O

We	O
did	O
this	O
ongoing	O
double	B:C0013072
-	I:C0013072
blind	I:C0013072
,	O
non-inferiority	O
study	I:C0008976
in	O
161	O
outpatient	O
centres	O
in	O
19	O
countries	O
.	O

We	O
did	O
this	O
ongoing	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
non-inferiority	B:C0008976
study	I:C0008976
in	O
161	O
outpatient	O
centres	O
in	O
19	O
countries	O
.	O

We	O
did	O
this	O
ongoing	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
non-inferiority	O
study	I:C0008976
in	O
161	O
outpatient	O
centres	B:C1708333
in	O
19	O
countries	O
.	O

We	O
did	O
this	O
ongoing	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
non-inferiority	O
study	I:C0008976
in	O
161	O
outpatient	O
centres	O
in	O
19	O
countries	B:C0454664
.	O

Patients	O
with	O
chronic	B:C0524909
HBV	I:C0524909
infection	I:C0524909
who	O
were	O
positive	O
for	O
the	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
(	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
)	O
were	O
randomly	O
assigned	O
(	O
2:1	O
)	O
to	O
receive	O
either	O
25	O
mg	O
tenofovir	O
alafenamide	I:C3713958
or	O
300	O
mg	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
with	O
matching	O
placebo	O
.	O

Patients	O
with	O
chronic	O
HBV	I:C0524909
infection	I:C0524909
who	O
were	O
positive	B:C1514241
for	O
the	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
(	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
)	O
were	O
randomly	O
assigned	O
(	O
2:1	O
)	O
to	O
receive	O
either	O
25	O
mg	O
tenofovir	O
alafenamide	I:C3713958
or	O
300	O
mg	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
with	O
matching	O
placebo	O
.	O

Patients	O
with	O
chronic	O
HBV	I:C0524909
infection	I:C0524909
who	O
were	O
positive	O
for	O
the	O
hepatitis	B:C0019167
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
(	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
)	O
were	O
randomly	O
assigned	O
(	O
2:1	O
)	O
to	O
receive	O
either	O
25	O
mg	O
tenofovir	O
alafenamide	I:C3713958
or	O
300	O
mg	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
with	O
matching	O
placebo	O
.	O

Patients	O
with	O
chronic	O
HBV	I:C0524909
infection	I:C0524909
who	O
were	O
positive	O
for	O
the	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
(	O
hepatitis	B:C0019167
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
)	O
were	O
randomly	O
assigned	O
(	O
2:1	O
)	O
to	O
receive	O
either	O
25	O
mg	O
tenofovir	O
alafenamide	I:C3713958
or	O
300	O
mg	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
with	O
matching	O
placebo	O
.	O

Patients	O
with	O
chronic	O
HBV	I:C0524909
infection	I:C0524909
who	O
were	O
positive	O
for	O
the	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
(	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
)	O
were	O
randomly	O
assigned	O
(	O
2:1	O
)	O
to	O
receive	O
either	O
25	O
mg	O
tenofovir	B:C3713958
alafenamide	I:C3713958
or	O
300	O
mg	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
with	O
matching	O
placebo	O
.	O

Patients	O
with	O
chronic	O
HBV	I:C0524909
infection	I:C0524909
who	O
were	O
positive	O
for	O
the	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
(	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
)	O
were	O
randomly	O
assigned	O
(	O
2:1	O
)	O
to	O
receive	O
either	O
25	O
mg	O
tenofovir	O
alafenamide	I:C3713958
or	O
300	O
mg	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
with	O
matching	O
placebo	O
.	O

Patients	O
with	O
chronic	O
HBV	I:C0524909
infection	I:C0524909
who	O
were	O
positive	O
for	O
the	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
(	O
hepatitis	O
B	I:C0019167
e	I:C0019167
antigen	I:C0019167
)	O
were	O
randomly	O
assigned	O
(	O
2:1	O
)	O
to	O
receive	O
either	O
25	O
mg	O
tenofovir	O
alafenamide	I:C3713958
or	O
300	O
mg	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
with	O
matching	O
placebo	B:C0032042
.	O

Randomisation	B:C0034656
was	O
done	O
by	O
a	O
computer	O
-	O
generated	O
allocation	O
sequence	O
(	O
block	O
size	I:C0456389
six	O
)	O
stratified	O
by	O
plasma	O
HBV	I:C3641250
DNA	I:C3641250
concentration	I:C3641250
and	O
previous	O
treatment	O
experience	O
.	O

Randomisation	O
was	O
done	O
by	O
a	O
computer	O
-	O
generated	O
allocation	O
sequence	O
(	O
block	B:C0456389
size	I:C0456389
six	O
)	O
stratified	O
by	O
plasma	O
HBV	I:C3641250
DNA	I:C3641250
concentration	I:C3641250
and	O
previous	O
treatment	O
experience	O
.	O

Randomisation	O
was	O
done	O
by	O
a	O
computer	O
-	O
generated	O
allocation	O
sequence	O
(	O
block	O
size	I:C0456389
six	O
)	O
stratified	O
by	O
plasma	B:C3641250
HBV	I:C3641250
DNA	I:C3641250
concentration	I:C3641250
and	O
previous	O
treatment	O
experience	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
the	O
proportion	O
of	O
patients	O
with	O
HBV	B:C1262160
DNA	I:C1262160
less	I:C1262160
than	O
29	O
IU	O
/	O
mL	O
at	O
week	O
48	O
in	O
all	O
patients	O
who	O
were	O
randomly	O
assigned	O
and	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
using	O
a	O
missing	O
-	I:C0025663
equals	I:C0025663
-	I:C0025663
failed	I:C0025663
approach	I:C0025663
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
the	O
proportion	O
of	O
patients	O
with	O
HBV	O
DNA	I:C1262160
less	I:C1262160
than	O
29	O
IU	O
/	O
mL	O
at	O
week	O
48	O
in	O
all	O
patients	O
who	O
were	O
randomly	O
assigned	O
and	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	B:C0013227
using	O
a	O
missing	O
-	I:C0025663
equals	I:C0025663
-	I:C0025663
failed	I:C0025663
approach	I:C0025663
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
the	O
proportion	O
of	O
patients	O
with	O
HBV	O
DNA	I:C1262160
less	I:C1262160
than	O
29	O
IU	O
/	O
mL	O
at	O
week	O
48	O
in	O
all	O
patients	O
who	O
were	O
randomly	O
assigned	O
and	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
using	O
a	O
missing	B:C0025663
-	I:C0025663
equals	I:C0025663
-	I:C0025663
failed	I:C0025663
approach	I:C0025663
.	O

The	O
pre-specified	O
non-inferiority	B:C0205284
margin	I:C0205284
was	O
10	O
%	O
.	O

Key	O
prespecified	O
safety	O
endpoints	O
were	O
bone	B:C0948168
and	O
renal	O
parameters	O
at	O
week	O
48	O
.	O

This	O
study	B:C0008976
is	O
registered	O
with	O
ClinicalTrials.gov	O
,	O
number	O
NCT01940471	O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials.gov	B:C4086204
,	O
number	O
NCT01940471	O
.	O

Of	O
the	O
1473	O
patients	O
screened	O
from	O
Sept	O
11	O
,	O
2013	O
,	O
to	O
Dec	O
20	O
,	O
2014	O
,	O
875	O
eligible	O
patients	O
were	O
randomly	O
assigned	O
and	O
873	O
received	O
treatment	O
(	O
581	O
with	O
tenofovir	B:C3713958
alafenamide	I:C3713958
and	O
292	O
with	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

Of	O
the	O
1473	O
patients	O
screened	O
from	O
Sept	O
11	O
,	O
2013	O
,	O
to	O
Dec	O
20	O
,	O
2014	O
,	O
875	O
eligible	O
patients	O
were	O
randomly	O
assigned	O
and	O
873	O
received	O
treatment	O
(	O
581	O
with	O
tenofovir	O
alafenamide	I:C3713958
and	O
292	O
with	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

371	O
(	O
64	O
%	O
)	O
patients	O
receiving	O
tenofovir	B:C3713958
alafenamide	I:C3713958
had	O
HBV	O
DNA	I:C1262160
less	I:C1262160
than	O
29	O
IU	O
/	O
mL	O
at	O
week	O
48	O
,	O
which	O
was	O
non-inferior	O
to	O
the	O
195	O
(	O
67	O
%	O
)	O
of	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
who	O
had	O
HBV	O
DNA	I:C1262160
less	I:C1262160
than	O
29	O
IU	O
/	O
mL	O
(	O
adjusted	O
difference	O
-	O
3·6	O
%	O
[	O
95	O
%	O
CI	O
-	O
9·8	O
to	O
2·6	O
]	O
;	O
p	O
=0·25	O
)	O
.	O

371	O
(	O
64	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
had	O
HBV	B:C1262160
DNA	I:C1262160
less	I:C1262160
than	O
29	O
IU	O
/	O
mL	O
at	O
week	O
48	O
,	O
which	O
was	O
non-inferior	O
to	O
the	O
195	O
(	O
67	O
%	O
)	O
of	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
who	O
had	O
HBV	O
DNA	I:C1262160
less	I:C1262160
than	O
29	O
IU	O
/	O
mL	O
(	O
adjusted	O
difference	O
-	O
3·6	O
%	O
[	O
95	O
%	O
CI	O
-	O
9·8	O
to	O
2·6	O
]	O
;	O
p	O
=0·25	O
)	O
.	O

371	O
(	O
64	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
had	O
HBV	O
DNA	I:C1262160
less	I:C1262160
than	O
29	O
IU	O
/	O
mL	O
at	O
week	O
48	O
,	O
which	O
was	O
non-inferior	O
to	O
the	O
195	O
(	O
67	O
%	O
)	O
of	O
patients	O
receiving	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
who	O
had	O
HBV	O
DNA	I:C1262160
less	I:C1262160
than	O
29	O
IU	O
/	O
mL	O
(	O
adjusted	O
difference	O
-	O
3·6	O
%	O
[	O
95	O
%	O
CI	O
-	O
9·8	O
to	O
2·6	O
]	O
;	O
p	O
=0·25	O
)	O
.	O

371	O
(	O
64	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
had	O
HBV	O
DNA	I:C1262160
less	I:C1262160
than	O
29	O
IU	O
/	O
mL	O
at	O
week	O
48	O
,	O
which	O
was	O
non-inferior	O
to	O
the	O
195	O
(	O
67	O
%	O
)	O
of	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
who	O
had	O
HBV	B:C1262160
DNA	I:C1262160
less	I:C1262160
than	O
29	O
IU	O
/	O
mL	O
(	O
adjusted	O
difference	O
-	O
3·6	O
%	O
[	O
95	O
%	O
CI	O
-	O
9·8	O
to	O
2·6	O
]	O
;	O
p	O
=0·25	O
)	O
.	O

Patients	O
given	O
tenofovir	B:C3713958
alafenamide	I:C3713958
had	O
a	O
significantly	O
smaller	O
decrease	O
in	O
bone	O
mineral	I:C0005938
density	I:C0005938
at	O
hip	O
(	O
mean	O
change	O
-	O
0·10	O
%	O
[	O
95	O
%	O
CI	O
-	O
0·29	O
to	O
0·09	O
]	O
vs	O
-	O
1·72	O
%	O
[	O
-	O
2·02	O
to	O
-	O
1·41	O
]	O
;	O
adjusted	O
difference	O
1·62	O
[	O
1·27	O
to	O
1·96	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
and	O
at	O
spine	O
(	O
mean	O
change	O
-	O
0·	O
42	O
%	O
[	O
-	O
0·66	O
to	O
-	O
0·17	O
]	O
vs	O
-	O
2·29	O
%	O
[	O
-	O
2·67	O
to	O
-	O
1·92	O
]	O
;	O
adjusted	O
difference	O
1·88	O
[	O
1·44	O
to	O
2·31	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
as	O
well	O
as	O
smaller	O
mean	O
increases	O
in	O
serum	O
creatinine	I:C0600061
at	O
week	O
48	O
(	O
0·01	O
mg/dL	O
[	O
0·00	O
-	O
0·02	O
]	O
vs	O
0·03	O
mg/dL	O
[	O
0·02-0·04	O
]	O
;	O
p	O
=0·02	O
)	O
.	O

Patients	O
given	O
tenofovir	O
alafenamide	I:C3713958
had	O
a	O
significantly	O
smaller	O
decrease	O
in	O
bone	B:C0005938
mineral	I:C0005938
density	I:C0005938
at	O
hip	O
(	O
mean	O
change	O
-	O
0·10	O
%	O
[	O
95	O
%	O
CI	O
-	O
0·29	O
to	O
0·09	O
]	O
vs	O
-	O
1·72	O
%	O
[	O
-	O
2·02	O
to	O
-	O
1·41	O
]	O
;	O
adjusted	O
difference	O
1·62	O
[	O
1·27	O
to	O
1·96	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
and	O
at	O
spine	O
(	O
mean	O
change	O
-	O
0·	O
42	O
%	O
[	O
-	O
0·66	O
to	O
-	O
0·17	O
]	O
vs	O
-	O
2·29	O
%	O
[	O
-	O
2·67	O
to	O
-	O
1·92	O
]	O
;	O
adjusted	O
difference	O
1·88	O
[	O
1·44	O
to	O
2·31	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
as	O
well	O
as	O
smaller	O
mean	O
increases	O
in	O
serum	O
creatinine	I:C0600061
at	O
week	O
48	O
(	O
0·01	O
mg/dL	O
[	O
0·00	O
-	O
0·02	O
]	O
vs	O
0·03	O
mg/dL	O
[	O
0·02-0·04	O
]	O
;	O
p	O
=0·02	O
)	O
.	O

Patients	O
given	O
tenofovir	O
alafenamide	I:C3713958
had	O
a	O
significantly	O
smaller	O
decrease	O
in	O
bone	O
mineral	I:C0005938
density	I:C0005938
at	O
hip	B:C0019552
(	O
mean	O
change	O
-	O
0·10	O
%	O
[	O
95	O
%	O
CI	O
-	O
0·29	O
to	O
0·09	O
]	O
vs	O
-	O
1·72	O
%	O
[	O
-	O
2·02	O
to	O
-	O
1·41	O
]	O
;	O
adjusted	O
difference	O
1·62	O
[	O
1·27	O
to	O
1·96	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
and	O
at	O
spine	O
(	O
mean	O
change	O
-	O
0·	O
42	O
%	O
[	O
-	O
0·66	O
to	O
-	O
0·17	O
]	O
vs	O
-	O
2·29	O
%	O
[	O
-	O
2·67	O
to	O
-	O
1·92	O
]	O
;	O
adjusted	O
difference	O
1·88	O
[	O
1·44	O
to	O
2·31	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
as	O
well	O
as	O
smaller	O
mean	O
increases	O
in	O
serum	O
creatinine	I:C0600061
at	O
week	O
48	O
(	O
0·01	O
mg/dL	O
[	O
0·00	O
-	O
0·02	O
]	O
vs	O
0·03	O
mg/dL	O
[	O
0·02-0·04	O
]	O
;	O
p	O
=0·02	O
)	O
.	O

Patients	O
given	O
tenofovir	O
alafenamide	I:C3713958
had	O
a	O
significantly	O
smaller	O
decrease	O
in	O
bone	O
mineral	I:C0005938
density	I:C0005938
at	O
hip	O
(	O
mean	O
change	O
-	O
0·10	O
%	O
[	O
95	O
%	O
CI	O
-	O
0·29	O
to	O
0·09	O
]	O
vs	O
-	O
1·72	O
%	O
[	O
-	O
2·02	O
to	O
-	O
1·41	O
]	O
;	O
adjusted	O
difference	O
1·62	O
[	O
1·27	O
to	O
1·96	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
and	O
at	O
spine	B:C0037949
(	O
mean	O
change	O
-	O
0·	O
42	O
%	O
[	O
-	O
0·66	O
to	O
-	O
0·17	O
]	O
vs	O
-	O
2·29	O
%	O
[	O
-	O
2·67	O
to	O
-	O
1·92	O
]	O
;	O
adjusted	O
difference	O
1·88	O
[	O
1·44	O
to	O
2·31	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
as	O
well	O
as	O
smaller	O
mean	O
increases	O
in	O
serum	O
creatinine	I:C0600061
at	O
week	O
48	O
(	O
0·01	O
mg/dL	O
[	O
0·00	O
-	O
0·02	O
]	O
vs	O
0·03	O
mg/dL	O
[	O
0·02-0·04	O
]	O
;	O
p	O
=0·02	O
)	O
.	O

Patients	O
given	O
tenofovir	O
alafenamide	I:C3713958
had	O
a	O
significantly	O
smaller	O
decrease	O
in	O
bone	O
mineral	I:C0005938
density	I:C0005938
at	O
hip	O
(	O
mean	O
change	O
-	O
0·10	O
%	O
[	O
95	O
%	O
CI	O
-	O
0·29	O
to	O
0·09	O
]	O
vs	O
-	O
1·72	O
%	O
[	O
-	O
2·02	O
to	O
-	O
1·41	O
]	O
;	O
adjusted	O
difference	O
1·62	O
[	O
1·27	O
to	O
1·96	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
and	O
at	O
spine	O
(	O
mean	O
change	O
-	O
0·	O
42	O
%	O
[	O
-	O
0·66	O
to	O
-	O
0·17	O
]	O
vs	O
-	O
2·29	O
%	O
[	O
-	O
2·67	O
to	O
-	O
1·92	O
]	O
;	O
adjusted	O
difference	O
1·88	O
[	O
1·44	O
to	O
2·31	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
as	O
well	O
as	O
smaller	O
mean	O
increases	O
in	O
serum	B:C0600061
creatinine	I:C0600061
at	O
week	O
48	O
(	O
0·01	O
mg/dL	O
[	O
0·00	O
-	O
0·02	O
]	O
vs	O
0·03	O
mg/dL	O
[	O
0·02-0·04	O
]	O
;	O
p	O
=0·02	O
)	O
.	O

The	O
most	O
common	O
adverse	B:C0877248
events	I:C0877248
overall	O
were	O
upper	O
respiratory	I:C0041912
tract	I:C0041912
infection	I:C0041912
(	O
51	O
[	O
9	O
%	O
]	O
of	O
581	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
vs	O
22	O
[	O
8	O
%	O
]	O
of	O
292	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
,	O
nasopharyngitis	O
(	O
56	O
[	O
10	O
%	O
]	O
vs	O
16	O
[	O
5	O
%	O
]	O
)	O
,	O
and	O
headache	O
(	O
42	O
[	O
7	O
%	O
]	O
vs	O
22	O
[	O
8	O
%	O
]	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	I:C0877248
overall	O
were	O
upper	B:C0041912
respiratory	I:C0041912
tract	I:C0041912
infection	I:C0041912
(	O
51	O
[	O
9	O
%	O
]	O
of	O
581	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
vs	O
22	O
[	O
8	O
%	O
]	O
of	O
292	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
,	O
nasopharyngitis	O
(	O
56	O
[	O
10	O
%	O
]	O
vs	O
16	O
[	O
5	O
%	O
]	O
)	O
,	O
and	O
headache	O
(	O
42	O
[	O
7	O
%	O
]	O
vs	O
22	O
[	O
8	O
%	O
]	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	I:C0877248
overall	O
were	O
upper	O
respiratory	I:C0041912
tract	I:C0041912
infection	I:C0041912
(	O
51	O
[	O
9	O
%	O
]	O
of	O
581	O
patients	O
receiving	O
tenofovir	B:C3713958
alafenamide	I:C3713958
vs	O
22	O
[	O
8	O
%	O
]	O
of	O
292	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
,	O
nasopharyngitis	O
(	O
56	O
[	O
10	O
%	O
]	O
vs	O
16	O
[	O
5	O
%	O
]	O
)	O
,	O
and	O
headache	O
(	O
42	O
[	O
7	O
%	O
]	O
vs	O
22	O
[	O
8	O
%	O
]	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	I:C0877248
overall	O
were	O
upper	O
respiratory	I:C0041912
tract	I:C0041912
infection	I:C0041912
(	O
51	O
[	O
9	O
%	O
]	O
of	O
581	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
vs	O
22	O
[	O
8	O
%	O
]	O
of	O
292	O
patients	O
receiving	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
,	O
nasopharyngitis	O
(	O
56	O
[	O
10	O
%	O
]	O
vs	O
16	O
[	O
5	O
%	O
]	O
)	O
,	O
and	O
headache	O
(	O
42	O
[	O
7	O
%	O
]	O
vs	O
22	O
[	O
8	O
%	O
]	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	I:C0877248
overall	O
were	O
upper	O
respiratory	I:C0041912
tract	I:C0041912
infection	I:C0041912
(	O
51	O
[	O
9	O
%	O
]	O
of	O
581	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
vs	O
22	O
[	O
8	O
%	O
]	O
of	O
292	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
,	O
nasopharyngitis	B:C0027441
(	O
56	O
[	O
10	O
%	O
]	O
vs	O
16	O
[	O
5	O
%	O
]	O
)	O
,	O
and	O
headache	O
(	O
42	O
[	O
7	O
%	O
]	O
vs	O
22	O
[	O
8	O
%	O
]	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	I:C0877248
overall	O
were	O
upper	O
respiratory	I:C0041912
tract	I:C0041912
infection	I:C0041912
(	O
51	O
[	O
9	O
%	O
]	O
of	O
581	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
vs	O
22	O
[	O
8	O
%	O
]	O
of	O
292	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
,	O
nasopharyngitis	O
(	O
56	O
[	O
10	O
%	O
]	O
vs	O
16	O
[	O
5	O
%	O
]	O
)	O
,	O
and	O
headache	B:C0018681
(	O
42	O
[	O
7	O
%	O
]	O
vs	O
22	O
[	O
8	O
%	O
]	O
)	O
.	O

22	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	B:C3713958
alafenamide	I:C3713958
and	O
12	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
experienced	O
serious	O
adverse	O
events	I:C0877248
,	O
none	O
of	O
which	O
was	O
deemed	O
by	O
the	O
investigator	O
to	O
be	O
related	O
to	O
study	O
treatment	I:C3161471
.	O

22	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
12	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
experienced	O
serious	O
adverse	O
events	I:C0877248
,	O
none	O
of	O
which	O
was	O
deemed	O
by	O
the	O
investigator	O
to	O
be	O
related	O
to	O
study	O
treatment	I:C3161471
.	O

22	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
12	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
experienced	O
serious	O
adverse	B:C0877248
events	I:C0877248
,	O
none	O
of	O
which	O
was	O
deemed	O
by	O
the	O
investigator	O
to	O
be	O
related	O
to	O
study	O
treatment	I:C3161471
.	O

22	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
12	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
experienced	O
serious	O
adverse	O
events	I:C0877248
,	O
none	O
of	O
which	O
was	O
deemed	O
by	O
the	O
investigator	B:C0008961
to	O
be	O
related	O
to	O
study	O
treatment	I:C3161471
.	O

22	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
12	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
experienced	O
serious	O
adverse	O
events	I:C0877248
,	O
none	O
of	O
which	O
was	O
deemed	O
by	O
the	O
investigator	O
to	O
be	O
related	O
to	O
study	B:C3161471
treatment	I:C3161471
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	B:C3713958
alafenamide	I:C3713958
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	O
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	O
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	I:C3713958
group	B:C1257890
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	O
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	O
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	I:C3713958
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	O
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	O
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	I:C3713958
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
group	B:C1257890
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	O
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	O
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	I:C3713958
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
group	O
had	O
grade	B:C0441800
3	O
or	O
4	O
laboratory	O
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	O
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	O
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	I:C3713958
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	B:C1853129
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	O
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	O
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	I:C3713958
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	B:C0201836
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	O
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	I:C3713958
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	O
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	B:C3713958
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	O
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	I:C3713958
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	O
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	O
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	I:C3713958
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	O
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	B:C0201899
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	I:C3713958
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	O
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	O
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	B:C3713958
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	I:C3713958
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	I:C1853129
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	O
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
and	O
AST	O
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	I:C3713958
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
)	O
.	O

In	O
patients	O
with	O
HBeAg	B:C0392390
-	I:C0392390
positive	I:C0392390
HBV	O
infection	I:C0524909
,	O
tenofovir	O
alafenamide	I:C3713958
was	O
non-inferior	O
to	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
,	O
and	O
had	O
improved	O
bone	O
and	O
renal	O
effects	O
.	O

In	O
patients	O
with	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
HBV	B:C0524909
infection	I:C0524909
,	O
tenofovir	O
alafenamide	I:C3713958
was	O
non-inferior	O
to	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
,	O
and	O
had	O
improved	O
bone	O
and	O
renal	O
effects	O
.	O

In	O
patients	O
with	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
HBV	O
infection	I:C0524909
,	O
tenofovir	B:C3713958
alafenamide	I:C3713958
was	O
non-inferior	O
to	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
,	O
and	O
had	O
improved	O
bone	O
and	O
renal	O
effects	O
.	O

In	O
patients	O
with	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
HBV	O
infection	I:C0524909
,	O
tenofovir	O
alafenamide	I:C3713958
was	O
non-inferior	O
to	O
tenofovir	B:C1099776
disoproxil	I:C1099776
fumarate	I:C1099776
,	O
and	O
had	O
improved	O
bone	O
and	O
renal	O
effects	O
.	O

In	O
patients	O
with	O
HBeAg	O
-	I:C0392390
positive	I:C0392390
HBV	O
infection	I:C0524909
,	O
tenofovir	O
alafenamide	I:C3713958
was	O
non-inferior	O
to	O
tenofovir	O
disoproxil	I:C1099776
fumarate	I:C1099776
,	O
and	O
had	O
improved	B:C0184511
bone	O
and	O
renal	O
effects	O
.	O

Longer	O
term	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
is	O
needed	O
to	O
better	O
understand	O
the	O
clinical	O
impact	O
of	O
these	O
changes	O
.	O

